^
Association details:
| Biomarker: | NRAS Q61H |
|---|---|
| Cancer: | Melanoma |
| Drug: | Yervoy (ipilimumab) (CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations
Excerpt:
Patient 6 (Q61HNRAS) presented with extensive metastatic disease and was started on ipilimumab. The tumour responded well with significant reduction in tumour burden and falling in RECIST scores.
DOI:
10.1038/srep11198 (2015)
